GT Biopharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
505 MONTGOMERY STREET, SAN FRANCISCO, CA, 94111
Mailing Address
505 MONTGOMERY STREET, SAN FRANCISCO, CA, 94111
Phone
(800) 304-9888
Fiscal Year End
1231
EIN
941620407
Financial Overview
FY2025
$8.30M
Net Income
$7.48M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 7, 2026 | View on SEC |
| 10-Q/A Quarterly report amendment | March 6, 2026 | View on SEC |
| 10-Q/A Quarterly report amendment | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 10-K Annual financial report | March 2, 2026 | View on SEC |
| S-1 IPO registration statement | January 21, 2026 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| S-1 IPO registration statement | October 24, 2025 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Progression of lead immunotherapy candidate GTB3650 into a Phase 1/2 study for relapsed/refractory AML.
- Promising safety profiles observed in initial dose-escalation phase of GTB3650 clinical trial.
Material Events
8-K
Financial Distress
March 2, 2026
High Impact
- GT Biopharma is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer.
- The financial restatement is an accounting correction and did not impact the company's actual operating cash flow or drug development progress.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.